Long-Term Realism and Cost-Effectiveness: Primary Prevention in Combatting Cancer and Associated Inequalities Worldwide

Journal of the National Cancer Institute

Volumn 107, Issue 12, 2015, Pages

  Bray, Freddie ^a   Jemal, Ahmedin ^b   Torre, Lindsey A ^b   Forman, David ^a   Vineis, Paolo ^c,d  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b AMERICAN CANCER SOCIETY   (United States)

^c School of Public Health and HuGeF Foundation   (Italy)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; HUMAN PAPILLOMA VIRUS VACCINE;

BRAZIL; CANCER INCIDENCE; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; ECONOMIC INEQUALITY; ENVIRONMENTAL EXPOSURE; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEALTH PROMOTION; HEPATITIS B; HUMAN; KAZAKHSTAN; LIVER CANCER; MALIGNANT NEOPLASM; MESOTHELIOMA; MIDDLE INCOME COUNTRY; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PALLIATIVE THERAPY; PREVALENCE; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SMOKING; VACCINATION; CHRONIC DISEASE; HEALTH CARE PLANNING; ORGANIZATION AND MANAGEMENT;

CHRONIC DISEASE; DELIVERY OF HEALTH CARE; HEALTH PLANNING; HUMANS;

EID: 85016730777     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv273     Document Type: Review

References (39)

1. Jemal A, Vineis P, Bray F, et al. The Cancer Atlas 2nd ed. Atlanta, GA: American Cancer Society; 2014.
2. Bray F, Soerjomataran I. The changing global burden of cancer: transitions in human development and implications for cancer prevention and control. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Disease Control Priorities, 3rd ed. Ed: Cancer; 2015.
3. Stuckler D, McKee M, Ebrahim S, et al. Manufacturing epidemics: the role of global producers in increased consumption of unhealthy commodities including processed foods, alcohol, and tobacco. PLoS Med. 2012;9(6):e1001235.
4. World Health Organization. WHO Report on the Global Tobacco Epidemic, 2013. Geneva: 2013.
5. Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012;13(8):790–801.
6. Bray F, Lortet-Tieulent J, Znaor A, et al. Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia. Vaccine. 2013;31 Suppl 7:H32–H45.
7. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1688–1694.
8. Arnold M, Pandeya N, Byrnes G, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16(1):36–46.
9. World Cancer Research Fund / American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington, D.C.: AICR; 2007.
10. World Health Organization. Global Status Report on Alcohol and Health 2014. Geneva: WHO Press; 2014.
11. Moore SP, Green AC, Bray F, et al. Survival disparities in Australia: an analysis of patterns of care and comorbidities among indigenous and non-indigenous cancer patients. BMC Cancer. 2014;14:517.
12. Thun MJ, Jemal A. How much of the decrease in cancer death rates in the United States is attributable to reductions in tobacco smoking? Tob Control. 2006;15(5):345–347.
13. International Agency for Research on Cancer. Cervix Cancer Screening. Lyon: IARC Press; 2004.
14. Vaccarella S, Franceschi S, Engholm G, et al. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer. 2014;111(5):965–969.
15. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403.
16. Kalager M, Zelen M, Langmark F, et al. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med. 2010;363(13):1203–1210.
17. Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1695–1698.
18. Chiang CJ, Yang YW, You SL, et al. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA. 2013;310(9):974–976.
19. Binagwaho A, Wagner CM, Gatera M, et al. Achieving high coverage in Rwanda’s national human papillomavirus vaccination programme. Bull World Health Organ. 2012;90(8):623–628.
20. Levy D, de Almeida LM, Szklo A. The Brazil SimSmoke policy simulation model: the effect of strong tobacco control policies on smoking prevalence and smoking-attributable deaths in a middle income nation. PLoS Med. 2012;9(11):e1001336.
21. Levy DT, Benjakul S, Ross H, et al. The role of tobacco control policies in reducing smoking and deaths in a middle income nation: results from the Thailand SimSmoke simulation model. Tob Control. 2008;17(1):53–59.
22. Jha P. Avoidable global cancer deaths and total deaths from smoking. Nat Rev Cancer. 2009;9(9):655–664.
23. World Health Organization. WHO Framework Convention on Tobacco Control Overview. http://www.who.int/fctc/text_download/en/index.html. Last accessed March 2, 2015.
24. National Center for Chronic Disease Prevention and Health Promotion Office on Smoking and Health. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. In. Atlanta (GA): Centers for Disease Control and Prevention (US); 2014.
25. Centers for Disease Control and Prevention. Best Practices for Comprehensive Tobacco Control Programs-2007. Atlanta, GA: October 2007.
26. Su CC, Lu JL, Tsai KY, et al. Reduction in arsenic intake from water has different impacts on lung cancer and bladder cancer in an arseniasis endemic area in Taiwan. Cancer Causes Control. 2011;22(1):101–108.
27. Chen Y, Ahsan H. Cancer burden from arsenic in drinking water in Bangladesh. Am J Public Health. 2004;94(5):741–744.
28. Hodgson JT, McElvenny DM, Darnton AJ, et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer. 2005;92(3):587–593.
29. Luengo-Fernandez R, Leal J, Gray A, et al. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14(12):1165–1174.
30. Agency for Healthcare Research and Quality Medical Expenditure Panel Survey. Total Expenses and Percent Distribution for Selected Conditions by type of Service: United States, 2012. http://meps.ahrq.gov/mepsweb/data_stats/tables_compendia_hh_interactive.jsp?_SERVICE=MEPSSocket0&_P R O G R A M = M E P S P G M . T C . S A S & F i l e = H C F Y 2 0 1 2 & T a b l e = H CFY2012_CNDXP_C&_Debug. Last accessed March 2, 2015.
31. Abdel-Wahab M, Bourque JM, Pynda Y, et al. Status of radiotherapy resources in Africa: an International Atomic Energy Agency analysis. Lancet Oncol. 2013;14(4):e168–e175.
32. Adesina A, Chumba D, Nelson AM, et al. Improvement of pathology in sub-Saharan Africa. Lancet Oncol. 2013;14(4):e152–e157.
33. World Health Organization. Global status report on noncommunicable diseases, 2014. 2014.
34. World Health Organization. Scaling up action against noncommunicable diseases: how much will it cost? France: 2011.
35. Goldie SJ, O’Shea M, Campos NG, et al. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine. 2008;26(32):4080–4093.
36. Chen PC, Lee YC, Tsai ST, et al. A cost-benefit analysis of the outpatient smoking cessation services in Taiwan from a societal viewpoint. Nicotine Tob Res. 2012;14(5):522–530.
37. Hurley SF, Matthews JP. Cost-effectiveness of the Australian National Tobacco Campaign. Tob Control. 2008;17(6):379–384.
38. SEO Economic Research. Cost-benefit analysis of dietary treatment. https://www.bda.uk.com/improvinghealth/healthprofessionals/cost_benefit_of_dietitians. Last accessed March 2, 2015.
39. Atun R, Jaffar S, Nishtar S, et al. Improving responsiveness of health systems to non-communicable diseases. Lancet. 2013;381(9867):690–697.